About 199,000 results
Open links in new tab
  1. Studies haven’t found for sure that Actos causes bladder cancer. Because Actos may increase the risk of bladder cancer, doctors typically won’t prescribe it to those who already have this condition. If you’ve had bladder cancer in the past, your doctor may suggest a different diabetes treatment for you.

    Actos: Side Effects, Dosage, Uses, What t…

    www.healthline.com/health/drugs/actos
    On December 12, 2016, FDA announced as a result of an updated review, that it has concluded that use of the type 2 diabetes medicine pioglitazone (brand names Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer.

    Pioglitazone - U.S. Food and Drug Admin…

    www.fda.gov/drugs/fda-drug-safety-podcasts/fda-dr…
    The study published today in The BMJ concludes that pioglitazone, known by the brand name Actos, is associated with an increased risk of bladder cancer for patients that use the drug, especially over a long period of time.

    Diabetes Drugs and Bladder Cancer Risk …

    www.healthline.com/health-news/study-connects-bl…
  2. People also ask
    Does Actos XR contain Glimepiride & Metformin?
    The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer. Sold as a single-ingredient product under the brand-name Actos. Also sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact).

    FDA Drug Safety Communication: Update to ongoing safety review of A…

    fda.gov
    Can I stop taking Actos If I have bladder cancer?
    Do not stop taking your Actos unless told to do so by your healthcare professional. FDA has not concluded that Actos increases the risk of bladder cancer. The Agency is reviewing this safety concern and will update the public when additional information is available. Talk to your healthcare professional if you have concerns about Actos.

    FDA Drug Safety Communication: Ongoing Safety Review of Actos

    fda.gov
    What is the risk of bladder cancer against never use?
    Among cumulative exposure categories < 10,500, 10,500–28,000, and > 28,000 mg, the overall effect size for risks of bladder cancer against never use were 1.12 (95%, CI 0.98–1.30), 1.09 (95% CI, 0.83–1.42), and 1.41 (95% CI, 1.06–1.88), respectively.

    Pioglitazone use and risk of bladder cancer: a systematic literature

    ncbi.nlm.nih.gov
    What is Actos used for?
    Actos is used along with diet and exercise to control blood sugar or improve control of blood sugar in adults with type 2 diabetes mellitus. Bladder cancer is estimated to occur in 20 per 100,000 persons per year in the United States and is thought to be higher in diabetics. 1

    FDA Drug Safety Communication: Ongoing Safety Review of Actos

    fda.gov
    Does Actos (pioglitazone) increase bladder cancer risk?
    [09-17-2010] The U.S. Food and Drug Administration (FDA) is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone), is associated with an increased risk of bladder cancer. Findings from studies in animals and humans suggest this is a potential safety risk that needs further study.

    FDA Drug Safety Communication: Ongoing Safety Review of Actos

    fda.gov
    Does Actos reduce HbA1c?
    Across the approved doses Actos reduced HbA1c compared to placebo by an average of 1.5%. In preclinical carcinogenicity studies of pioglitazone, bladder tumors were observed in male rats receiving doses of pioglitazone that produced blood drug levels equivalent to those resulting from a clinical dose.

    FDA Drug Safety Communication: Ongoing Safety Review of Actos

    fda.gov
    Feedback
  3. Food and Drug Administration (.gov)
    https://www.fda.gov › drugs › drug-safety-and...

    FDA Drug Safety Communication: Update to ongoing safety …

  4. Food and Drug Administration (.gov)
    https://www.fda.gov › drugs › drug-safety-and...

    FDA Drug Safety Communication: Updated FDA review concludes …

  5. Studies of Actos and Bladder Cancer
    National Center for Biotechnology Information
    Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
    Pioglitazone belongs to the thiazolidinediones, a class of antidiabetic drugs that exert their action by binding to the peroxisome proliferator-activated receptor gamma (PPAR-Îł) [1]. It was approved by the US Food and Drug Administration (FDA) in 1999 and European Medicines Agency (EMA) in 2000 for ...
    Author: Elena Filipova…
    Published: 2017/08
    Publication: Diabetes …
    PubMed
    Pioglitazone and bladder cancer risk: a systematic review and meta-analysis
    Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results. We systematically searched PubMed, Embase, and Cochrane Central ...
    Author: Huilin Tang
    Published: 2018/4
    Keywords: Bladder ca…
    National Center for Biotechnology Information
    Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies
    The burden of diabetes has been rising with its increasing prevalence. Currently, type 2 diabetes mellitus (T2DM) presents a global public health problem not only in industrialized countries, but across the globe. An estimated 422 million individuals or 8.5% of the world’s population had diabetes in...
    Author: Juha Mehtälä, …
    Published: 2019/01
    Publication: Diabetol I…
    PubMed
    Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
    Aims: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analy...
    Author: M Ferwana
    Published: 2013/9
    Keywords: Pioglitazon…
    PubMed
    Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
    In preclinical studies, pioglitazone was associated with bladder cancer in male rats (but not in female rats, mice dogs or monkeys). Because of this association, the Federal Drug Administration requested a large 10year epidemiological study to evaluate whether there was an association between bladde...
    Author: Mayer B David…
    Published: 2016/8
    Keywords: Actos; Blad…
  6. National Center for Biotechnology Information
    https://www.ncbi.nlm.nih.gov › pmc › articles

    Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis

    Tags:
    Bladder cancer
    Type 2 diabetes
    Publish Year:2017
    Published:2017/08
  7. nih.gov
    https://pmc.ncbi.nlm.nih.gov › articles

    Use of thiazolidinediones and the risk of bladder cancer among …

    Tags:
    Bladder cancer
    Type 2 diabetes
  8. PubMed
    https://pubmed.ncbi.nlm.nih.gov

    Pioglitazone and bladder cancer risk: a systematic review and meta ...

    Tags:
    Bladder cancer
    Publish Year:2018
  9. National Center for Biotechnology Information
    https://www.ncbi.nlm.nih.gov › pmc › articles

    Pioglitazone use and risk of bladder cancer: a systematic literature ...

    Tags:
    Bladder cancer
    Publish Year:2019
    Diabetol Int. 2019 Jan; 10(1): 24-36.
  10. Food and Drug Administration (.gov)
    https://www.fda.gov › drugs › drug-safety-and...

    FDA Drug Safety Communication: Ongoing Safety Review of Actos ...

    Tags:
    Bladder cancer
    Potential
  11. The BMJ
    https://www.bmj.com › content

    Pioglitazone use and risk of bladder cancer: population …

    Mar 30, 2016 · Compared with no thiazolidinedione use, the use of pioglitazone was associated with an increased risk of incident bladder cancer (121.0 v 88.9 per 100 000 person years; adjusted hazard ratio 1.63, 95% confidence interval …

    Tags:
    Bladder cancer
    Publish Year:2016
  12. The BMJ
    https://www.bmj.com › content

    Pioglitazone and the risk of bladder cancer | The BMJ

    May 31, 2012 · A linked study found that pioglitazone doubled the risk of bladder cancer in patients with diabetes. The authors review the evidence, the pharmacological profile, and the clinical implications of pioglitazone exposure.

    Tags:
    Bladder cancer
    Publish Year:2012
  13. PubMed
    https://pubmed.ncbi.nlm.nih.gov

    Pioglitazone and risk of bladder cancer: a meta-analysis of

    Tags:
    Bladder cancer
    Publish Year:2013